BridgeBio Pharma Inc. (BBIO)
NASDAQ: BBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
BBIO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $13.00B
- Forward P/E
- 2,420.82
- EPS (TTM)
- -$3.56
- Dividend yield
- None
- 52-week range
- 52.75 – 93.42
- Day range
- 66.15 – 67.57
- Volume / Avg
- 2.06M / 2.76M
- Beta
- —
- Shares outstanding
- 195.49M
- Next earnings
- Nov 4, 2026
52-week range
BBIO stock today
On Oct 7, BBIO ended the session at $66.50, shedding $0.46 (0.69%), versus the S&P 500's 0.22% decline. At this level, BBIO sits in the middle of its 52-week range of $52.75 to $93.42: 28.8% below the high, set on Jul 9, 2026 and 26.1% above the low. BBIO is down 13.1% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 22.6%.
BridgeBio Pharma has posted a net loss over the last twelve months (EPS of -$3.56), so its P/E ratio is not meaningful. BridgeBio Pharma's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About BridgeBio Pharma
Company profileBridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Neil Kumar Ph.D.
- Headquarters
- Palo Alto, CA
- Employees
- 999
- IPO year
- 2019
- Website
- bridgebio.com
Financial highlights
Full financialsIn fiscal 2025, BridgeBio Pharma generated $502.1 million in revenue, up 126.3% from fiscal 2024, its 2nd consecutive year of revenue growth. BridgeBio Pharma reported a net loss of $732.9 million, compared with a loss of $543.3 million a year earlier. Gross margin was 95.8% (down from 98.3%) and operating margin -104.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $502.08M | $221.90M | $9.30M | $77.65M | $69.72M |
| Growth | +126.26% | +2285.27% | -88.02% | +11.38% | +745.14% |
| Net income | $-732.94M | $-543.35M | $-653.25M | $-484.65M | $-586.45M |
| EPS (diluted) | $-3.78 | $-2.88 | $-3.95 | $-3.26 | $-3.90 |
Analyst forecast
ForecastConsensus (22 analysts)
strong_buy
Avg. price target
$109.05+63.98%
- Strong buy 5
- Buy 14
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-0.67
- Last reported (Q2 2026)
- Aug 10, 2026
- EPS actual vs est.
- $-0.78 vs —
BBIO news
All BBIO newsBridgeBio Pharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CORTCorcept Therapeutics Incorporated | 119.60 | +0.03% | $12.93B | vs BBIO |
| SMMTSummit Therapeutics Inc. | 17.95 | +3.70% | $14.32B | vs BBIO |
| MDGLMadrigal Pharmaceuticals Inc. | 487.72 | -1.76% | $11.27B | vs BBIO |
| JAZZJazz Pharmaceuticals plc | 231.19 | -0.09% | $15.01B | vs BBIO |
| ELANElanco Animal Health Incorporated | 22.36 | -0.53% | $11.17B | vs BBIO |
| ASNDAscendis Pharma A/S | 228.41 | +1.04% | $15.03B | vs BBIO |
| BMRNBioMarin Pharmaceutical Inc. | 55.20 | -1.81% | $10.69B | vs BBIO |
| RDYDr. Reddy's Laboratories Ltd | 12.27 | -1.76% | $10.22B | vs BBIO |
Indexes, lists and sector
BridgeBio Pharma stock FAQ
What is BridgeBio Pharma's stock price today?
BBIO last traded at $66.50 as of Oct 7, 4:00 PM EDT, down 0.69% on the day. Prices are delayed at least 15 minutes.
When is BridgeBio Pharma's next earnings date?
BridgeBio Pharma is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-0.67.
Who is BridgeBio Pharma's CEO?
Dr. Neil Kumar Ph.D. is the chief executive officer of BridgeBio Pharma Inc., which has about 999 employees.
What is the BBIO 52-week high?
The 52-week high for BBIO is $93.42 and the 52-week low is $52.75. The stock is currently 28.8% below its high.